AI assistant
GALECTIN THERAPEUTICS INC — Director's Dealing 2013
Nov 5, 2013
33422_dirs_2013-11-05_7d0ff5dc-db74-454c-9ed7-b8050575742e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2013-11-01
Reporting Person: Martin Rod D (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2013-11-01 | Common Stock | M | 150000 | $3.00 | Acquired | 9407422 | Indirect |
| 2013-11-01 | Common Stock | M | 50000 | $3.00 | Acquired | 9457422 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2013-11-01 | Class A-2 Warrant (right to buy) | $3.00 | M | 150000 | Disposed | 2014-05-13 | Common Stock (50000) | Indirect |
| 2013-11-01 | Class A-2 Warrant (right to buy) | $3.00 | M | 50000 | Disposed | 2014-06-30 | Common Stock (50000) | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 91488 | Direct |
Footnotes
F1: Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Martin disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F2: On May 13, 2009, 10X Fund, L.P. purchased (a) 450,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 150,000 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 150,000 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 600,000 shares of Common Stock for $3.00 per share, for aggregate consideration of $900,000.
F3: On June 30, 2009, 10X Fund, L.P. purchased (a) 250,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 833,333 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 83,333 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 333,333 shares of Common Stock for $3.00 per share, for aggregate consideration of $500,000.